Pre-order Enquiry
Request Free Sample
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2021-2027
SKU ID : QYR-17253056 | Publishing Date : 25-Jan-2021 | No. of pages : 95
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2021-2027
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Vitamin E & Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Elafibranor
1.2.5 Selonsertib & Cenicriviroc
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2016-2027)
2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Dynamic
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2016-2021)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2020
3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2022-2027)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2016-2021)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type
10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application
10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Conatus Pharmaceuticals
11.2.1 Conatus Pharmaceuticals Company Details
11.2.2 Conatus Pharmaceuticals Business Overview
11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.2.5 Conatus Pharmaceuticals Recent Development
11.3 Enzo Biochem
11.3.1 Enzo Biochem Company Details
11.3.2 Enzo Biochem Business Overview
11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.3.5 Enzo Biochem Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Details
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Genfit
11.5.1 Genfit Company Details
11.5.2 Genfit Business Overview
11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.5.5 Genfit Recent Development
11.6 Gilead
11.6.1 Gilead Company Details
11.6.2 Gilead Business Overview
11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.6.5 Gilead Recent Development
11.7 Horizon Pharma
11.7.1 Horizon Pharma Company Details
11.7.2 Horizon Pharma Business Overview
11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.7.5 Horizon Pharma Recent Development
11.8 Immuron
11.8.1 Immuron Company Details
11.8.2 Immuron Business Overview
11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.8.5 Immuron Recent Development
11.9 Intercept Pharmaceuticals
11.9.1 Intercept Pharmaceuticals Company Details
11.9.2 Intercept Pharmaceuticals Business Overview
11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.9.5 Intercept Pharmaceuticals Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2021-2027
List of TablesTable 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Vitamin E & Pioglitazone
Table 3. Key Players of Obeticholic Acid (OCA)
Table 4. Key Players of Elafibranor
Table 5. Key Players of Selonsertib & Cenicriviroc
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2016-2021)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2022-2027)
Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2016-2021)
Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2020)
Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 66. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Conatus Pharmaceuticals Company Details
Table 69. Conatus Pharmaceuticals Business Overview
Table 70. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 71. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 72. Conatus Pharmaceuticals Recent Development
Table 73. Enzo Biochem Company Details
Table 74. Enzo Biochem Business Overview
Table 75. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 76. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 77. Enzo Biochem Recent Development
Table 78. Galmed Pharmaceuticals Company Details
Table 79. Galmed Pharmaceuticals Business Overview
Table 80. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 81. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 82. Galmed Pharmaceuticals Recent Development
Table 83. Genfit Company Details
Table 84. Genfit Business Overview
Table 85. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 86. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 87. Genfit Recent Development
Table 88. Gilead Company Details
Table 89. Gilead Business Overview
Table 90. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 91. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 92. Gilead Recent Development
Table 93. Horizon Pharma Company Details
Table 94. Horizon Pharma Business Overview
Table 95. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 96. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 97. Horizon Pharma Recent Development
Table 98. Immuron Company Details
Table 99. Immuron Business Overview
Table 100. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 101. Immuron Recent Development
Table 102. Intercept Pharmaceuticals Company Details
Table 103. Intercept Pharmaceuticals Business Overview
Table 104. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 105. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 106. Intercept Pharmaceuticals Recent Development
Table 107. Novo Nordisk Company Details
Table 108. Novo Nordisk Business Overview
Table 109. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 110. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021) & (US$ Million)
Table 111. Novo Nordisk Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2022-2027)
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2020
Figure 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2020
Figure 18. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 22. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 23. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 24. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 28. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 29. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 30. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2016-2027)
Figure 40. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 60. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 61. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 62. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 63. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 64. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 65. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 66. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 67. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 68. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Keyplayers in Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2021-2027
AstraZenecaConatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
